Latest Commercialization News

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Renascor Resources has marked significant progress in its Purified Spherical Graphite (PSG) demonstration plant development, securing a site and completing initial production runs ahead of commissioning in late 2025.

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

Lion Energy Limited reports significant progress in its green hydrogen project at Port of Brisbane and confirms major oil and gas prospects in Indonesia, setting the stage for future drilling and commercial development.

Anax Metals has confirmed the success of its scaled-up bioleaching technology, achieving copper recoveries of up to 80% and zinc recoveries exceeding 90%, reinforcing its strategic position in Pilbara's base metals sector.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

AVADA Group Limited reports a positive cash flow for Q4 2024, supported by increased collections and operational consolidation, even as government funding shifts delay project starts.

Arrow Minerals has secured $7 million through a well-supported placement to advance its flagship Niagara Bauxite and Simandou North Iron projects in Guinea, setting the stage for key resource milestones and development studies.

Close the Loop Limited has ended acquisition discussions with Adamantem Capital but remains confident in its standalone growth strategy, projecting steady revenue and an EBITDA range of $11m-$13m for the first half of 2025.

Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Galan Lithium Limited has announced a substantial 150% increase in its Candelas Mineral Resource to 1.6 Mt LCE, lifting its total Hombre Muerto West resource to 9.5 Mt LCE and securing a spot among the world’s top 10 lithium projects.